genedrive plc announced successful results of the first field study of its Genedrive® Hetaptitis C (HCV) ID Kit in Africa. The study, performed in Johannesburg at Lancet Laboratories, was designed to verify genedrive HCV's assay performace across the diverse genotypes which are prevalent in Africa compared to Europe. In a cohort of 130 clinical samples from South Africa, Kenya, Ghana, Nigeria, Uganda, and other Sub-Saharan countries, the Genedrive® HCV ID Kit demonstrated sensitivity and specificity of 100% compared to the Abbott M2000 HCV Real time assay as a reference. The cohort was composed mostly of HCV genotypes 1a, 4, and 1b, with the remaining 16% samples from genotypes 2, 3, and 5. The test also demonstrated efficiency of 95.4% (result achieved first attempt).